What changed
$MRNA — BUY 📊 | 6 MONTHS THESIS
🎯 Q2 2026 | EPS $-2.19 vs $-2.19 ➖
💡 Consensus expects continued revenue erosion and cash burn without near-term pipeline catalysts, but our variant view is that cost controls and upcoming data readouts (flu/COVID combo, RSV) will positively surprise, driving a sentiment shift. The EPS beat of $0.48 versus estimates is the first signal of this turnaround.
📉 Reward/risk: 1.88:1
🏢 Business Quality: 6/10 - Strong mRNA platform and diverse pipeline, but currently concentrated in a declining COVID vaccine market with negative earnings and high cash burn.
📊 Valuation: fair — EV/Sales of ~5x on estimated 2026 revenue, below historical average of 10x, in line with struggling biotech peers but not yet pricing in...
📊 Our read: BUY. Full analysis →
https://stockduty.xyz/s/MRNA0617